stockportfolio.pro
Stocks / LGND vs SHC
LGND vs SHC
Ligand Pharmaceuticals Incorporated and Sotera Health Company side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Ligand Pharmaceuticals Incorporated (LGND) | Sotera Health Company (SHC) | |
|---|---|---|
| Market cap | $5.0B | $4.7B |
| Revenue (latest FY) | $268.09M | $1.16B |
| Net income (latest FY) | $124.45M | $77.95M |
| Revenue growth (5y CAGR) | 10.4% | 7.3% |
| Net margin | 46.4% | 6.7% |
| Return on equity | 12.2% | 12.9% |
| P/E ratio | 32.4 | 39.9 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 6 | 4 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open LGND — free Open SHC — freeFrequently asked questions
Which is bigger, LGND or SHC?
Ligand Pharmaceuticals Incorporated is larger by market capitalization — $5.0B versus $4.7B.
Which grows faster, LGND or SHC?
Over the last five fiscal years, Ligand Pharmaceuticals Incorporated grew revenue faster — 10.4%/yr versus 7.3%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.